Triple therapy for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests combining three treatments—a targeted radiation drug (177Lu-PSMA), a PARP inhibitor (olaparib), and an immunotherapy (pembrolizumab)—for men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to see if this combination can shrink tumors and slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a diagnosis of prostate cancer that has spread and is growing despite hormone therapy.
- You must have a PSMA PET scan showing high levels of the PSMA marker on your cancer cells.
- You must have progressed on at least one hormone therapy like enzalutamide, abiraterone, or apalutamide.
- You must have adequate kidney, liver, and blood counts (your doctor will check this).
- You must not have had chemotherapy for this stage of cancer, prior immunotherapy, PARP inhibitors, or radionuclide therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two ways of giving a radioactive drug (177Lu-PSMA-617) designed to find and destroy prostate cancer cells. It tests whether adjusting the dose based on your individual tumor’s activity works better than a fixed standard dose.
This trial is testing a new combination therapy for men with advanced prostate cancer that has stopped responding to hormone treatment. The goal is to see if this treatment can shrink tumors or slow down the cancer, and it may offer a new option when standard treatments have not worked.
This trial tests a new combination therapy for advanced prostate cancer that has stopped responding to standard hormone treatments. It combines a radioactive targeted treatment (Lutetium-177 DGUL) with an immunotherapy drug (pembrolizumab) to see if it can shrink tumors and slow the cancer's growth.
This study combines two treatments: pembrolizumab, which helps your immune system fight cancer, and a targeted radioactive medicine (177Lu-PSMA-617) that seeks out and damages prostate cancer cells. It may help men whose prostate cancer has spread despite initial hormone therapy.
This trial tests a new combination of two drugs for men with advanced prostate cancer that has stopped responding to standard hormone therapy or chemotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a new treatment that targets a protein called PSMA found on prostate cancer cells. It uses a radioactive form of the treatment to try to kill cancer cells while limiting damage to healthy cells. This study is for men with advanced prostate cancer that has stopped responding to other treatments.
Hear when a new Metastatic Castrate Resistant Prostate Cancer (mCRPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.